AI-generated analysis. Always verify with the original filing.
LeonaBio, Inc., a clinical-stage biopharmaceutical company, filed this S-1/A to register 5,502,402 shares of common stock issuable upon the exercise of a pre-funded warrant held by selling stockholder Sermonix Pharmaceuticals, Inc., which the company will not receive proceeds from.
LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs, specifically treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company recently underwent a strategic transformation, changing its name from Athira Pharma, Inc. to LeonaBio, Inc. in January 2026. Its lead drug candidates include lasofoxifene, currently in a Phase 3 clinical trial (ELAINE-3), and ATH-1105, in Phase 2 development. The company operates in the highly competitive and capital-intensive biotechnology sector, where success is contingent upon clinical trial outcomes and regulatory approvals.
This registration statement on Form S-1/A relates to a secondary offering of 5,502,402 shares of common stock by selling stockholder Sermonix Pharmaceuticals, Inc. These shares are issuable upon the exercise of a pre-funded warrant issued in December 2025 as partial consideration for an exclusive license to develop and commercialize lasofoxifene. Consequently, LeonaBio will not receive any proceeds from the sale of these shares by the selling stockholder. The company may only receive nominal gross proceeds of approximately $5,502 if the pre-funded warrant is exercised for cash at an exercise price of $0.001 per share. The warrant includes a beneficial ownership limitation of 4.99%, preventing Sermonix from owning more than that percentage of the company's outstanding common stock upon exercise.
Financially, the company is in the clinical development stage, which typically implies significant cash burn and a lack of revenue. While specific financial figures were not detailed in the provided text, the company explicitly stated it has never paid dividends and does not anticipate doing so in the foreseeable future, intending to retain all funds for operations. The company is classified as a 'smaller reporting company' and a 'non-accelerated filer,' which allows for reduced reporting requirements. The common stock is listed on the Nasdaq Capital Market under the ticker symbol 'LONA,' with a closing price of $8.42 on March 16, 2026.
Ownership is concentrated among institutional investors and insiders. Perceptive Entities holds a significant 19.99% stake, while insiders and directors collectively own 25.12%. The offering represents a potential dilution event for existing shareholders, though the exact impact depends on the number of shares ultimately sold by the selling stockholder. Key risks include the inherent uncertainties of clinical drug development, the need for additional funding, and reliance on third-party manufacturers and clinical trial operators. The company's recent licensing transaction with Sermonix suggests a strategic pivot or expansion of its pipeline, specifically centering on lasofoxifene as a key asset.
Shares Offered
23,031,494
Shares Offered
5,502,402
Share Type
Common Stock
Exchange
Nasdaq Capital Market
Ticker
LONA
Use of Proceeds: We will not receive any of the proceeds from the sale of our securities by the selling stockholder. We intend to use the net proceeds, if any, from the cash exercise of the pre-funded warrants... for working capital purposes and to advance lasofoxifene and the drug candidates in our existing pipeline.
A clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).